Eisai

Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires

Retrieved on: 
Thursday, April 4, 2024
Haddock, Growth, CFO, Eisai, Patient, ELK, Pharmacy, University, Senior, Express Scripts, IQVIA, Economics, Management

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.

Key Points: 
  • ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.
  • Orsini Specialty Pharmacy welcomes Victor Haddock and Lynda Parker to Executive Leadership Team.
  • Haddock has over 25 years of financial leadership experience in the healthcare sector, with a demonstrated ability to lead business strategies, implement change and build successful teams.
  • He most recently served as CFO of Triple-S Management in Puerto Rico, and he has held leadership positions at MagellanRx and Express Scripts.

BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Amyloid, Brain, Disease, Eisai, Patient, Research, European Grand Prix

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.

Key Points: 
  • "Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.
  • Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease.
  • By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
  • La Fondation Recherche Alzheimer was founded in 2004 and aims to improve the diagnosis of Alzheimer's disease and pave the way for effective treatments.

BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Amyloid, Brain, Disease, Eisai, Patient, Research, European Grand Prix

"Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.

Key Points: 
  • "Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt.
  • Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease.
  • By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
  • La Fondation Recherche Alzheimer was founded in 2004 and aims to improve the diagnosis of Alzheimer's disease and pave the way for effective treatments.

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Retrieved on: 
Monday, March 11, 2024
Diagnosis, Brain, Conference, Lecanemab, Disease, Incidence, Alpha-synuclein, Eisai, Patient, CAA, ARIA, DSM-IV codes, Antibody, Safety, Clarity, Pharmaceutical industry

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.

Key Points: 
  • BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.
  • Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aβ aggregates (fibrils), to reduce both Aβ protofibrils and Aβ plaques in the brain.
  • The difference in binding to CAA[1] was presented, with lecanemab having lower binding to CAA than most other antibodies.
  • This could explain the difference in the adverse event ARIA[2] seen between different antibodies, with lecanemab showing relatively low incidence of ARIA.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024
OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Health Technology, Senior, Pathology, Eisai, Growth, Deficit spending, History, Patient, Dementia, CSF, Diagnosis, PET, Medical imaging

C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

Key Points: 
  • C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
  • C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests , which are innovative blood tests intended for use in patients with cognitive impairment.
  • These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
  • “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MRK, Research, CRL, New Drug Application, Investment, Eisai, Growth, Sale, Parent, Novin, Focal segmental glomerulosclerosis, Streptococcus, LGND, FSGS, Breakthrough therapy, BLA, AED, GAAP, Therapy, NASH, Liver, NDA, Depreciation, Breast cancer, Total, Forecasting, Perampanel, Shanda, Telecanthus, ID, Retirement, PDUFA, Vaccine, Symantec Endpoint Protection, Type 2 diabetes, Safety, VRNA, Molluscum contagiosum, F2, Acquisition, Caregiver, Merck, AASLD, FDA, Telephone, Food, Pneumonia, Income tax, Hepatology, COVID-19, Element, Patient, SPA, Pharmaceutical industry

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, General Health, Pharmaceutical, Health, Eisai, Drug development, AED, Patient, Epilepsy, LGND, AMPA, Seizure, Pharmaceutical industry

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
  • Fycompa is formulated with Captisol®, a Ligand technology.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Under the terms of the agreement, Ligand is entitled to a royalty on sales of intravenous Fycompa.

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

Retrieved on: 
Thursday, March 7, 2024
FY, Eisai, Alzheimer's disease, JPY

STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.
  • According to Eisai's simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on March 7, 2023, at 06:30 a.m. CET.

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

Retrieved on: 
Thursday, March 7, 2024
FY, Eisai, Alzheimer's disease, JPY

STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.
  • According to Eisai's simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on March 7, 2023, at 06:30 a.m. CET.